These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33889275)

  • 1. Nanotechnology and pancreatic cancer management: State of the art and further perspectives.
    Caputo D; Pozzi D; Farolfi T; Passa R; Coppola R; Caracciolo G
    World J Gastrointest Oncol; 2021 Apr; 13(4):231-237. PubMed ID: 33889275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
    Caputo D; Caracciolo G
    Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology Meets Oncology: A Perspective on the Role of the Personalized Nanoparticle-Protein Corona in the Development of Technologies for Pancreatic Cancer Detection.
    Caputo D; Quagliarini E; Pozzi D; Caracciolo G
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins.
    Caputo D; Coppola A; Quagliarini E; Di Santo R; Capriotti AL; Cammarata R; Laganà A; Papi M; Digiacomo L; Coppola R; Pozzi D; Caracciolo G
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hot topics in pancreatic cancer management.
    Caputo D
    World J Gastrointest Surg; 2023 Feb; 15(2):121-126. PubMed ID: 36896312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test.
    Digiacomo L; Quagliarini E; Pozzi D; Coppola R; Caracciolo G; Caputo D
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection.
    Caputo D; Quagliarini E; Coppola A; La Vaccara V; Marmiroli B; Sartori B; Caracciolo G; Pozzi D
    Int J Surg; 2023 Oct; 109(10):2934-2940. PubMed ID: 37352522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going.
    Coppola A; Farolfi T; La Vaccara V; Iannone I; Giovinazzo F; Panettieri E; Tarallo M; Cammarata R; Coppola R; Caputo D
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.
    Sielaff CM; Mousa SA
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1205-1217. PubMed ID: 29721665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study.
    Caputo D; Cartillone M; Cascone C; Pozzi D; Digiacomo L; Palchetti S; Caracciolo G; Coppola R
    Pancreatology; 2018 Sep; 18(6):661-665. PubMed ID: 29914752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives.
    Coppola A; La Vaccara V; Farolfi T; Fiore M; Cammarata R; Ramella S; Coppola R; Caputo D
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
    Frappart PO; Hofmann TG
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
    Wang Z; Wu B; Nie G; Wei J; Li Y
    Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review study on early detection of pancreatic ductal adenocarcinoma using artificial intelligence assisted diagnostic methods.
    Sijithra PC; Santhi N; Ramasamy N
    Eur J Radiol; 2023 Sep; 166():110972. PubMed ID: 37454557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
    Markowski A; Jaromin A; Migdał P; Olczak E; Zygmunt A; Zaremba-Czogalla M; Pawlik K; Gubernator J
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu X; Bhandari K; Xu C; Morris K; Ding WQ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.
    McGowan R; Sally Á; McCabe A; Moran BM; Finn K
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in the diagnosis of pancreatic cancer.
    Vanek P; Eid M; Psar R; Zoundjiekpon V; Urban O; Kunovský L
    Vnitr Lek; 2022; 68(6):363-370. PubMed ID: 36316197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.